Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28881873 | 0.79 | CHRM3 (0.34) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL28466983 | 0.77 | CHRM3 (0.35) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL21693727 | 0.75 | CHRM3 (0.33) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL3446589 | 0.73 | CHRM3 (0.33) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL7041565 | 0.73 | CHRM3 (0.33) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL8125370 | 0.73 | CHRM3 (0.33) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL11262229 | 0.73 | CHRM3 (0.33) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL11258232 | 0.72 | CHRM3 (0.32) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL31272234 | 0.70 | SLC6A3 (0.33) | CHRM3 | |
| SCHEMBL8124602 | 0.69 | SLC6A3 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303549-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RES & DEV (FR) | 2013-11-14 | — | — | US | disclosed |
| US-8513297-B2 | Biaromatic compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20120121527-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARy TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-05-17 | — | — | US | disclosed |
| US-8129416-B2 | Biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-03-06 | — | — | US | disclosed |
| EP-1814871-B1 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20080027077-A1 | Novel biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-31 | — | — | US | disclosed |
| EP-1814871-A2 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006053791-A2 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027077-A1 | Novel biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | CHRM3 1444/4885LMNA 3072/4885CHRM2 1116/4885 |
| US-20130303549-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARD, PPARA | CHRM3 1593/4885LMNA 3522/4885CHRM2 1199/4885 |
| US-20120121527-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARy TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARD, PPARA | CHRM3 1593/4885LMNA 3522/4885CHRM2 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.